DCM Shriram Fine Chemicals Share Price & Earnings Call Analysis
- Market cap
- ₹234 Cr
- ROE
- -0.29%
- Price to sales
- 0.62
- Debt to equity
- 0.06
- 52W high / low
- ₹52.5 / ₹17.3
- EBITDA margin
- 0.38%
- Net profit margin
- -0.16%
- Promoter holding
- 50.11%
- Sales (last year)
- ₹378 Cr
DCM Shriram Ltd is a producer of Pharmaceutical Intermediates, particularly in the Anti-Infective segment using Optical Isomer separation as its core competence.[1]
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Chemicals & Petrochemicals companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 0–2% | ₹234 Cr | 3.0 | |
| 2 | 40%+ | Flat | ₹3,888 Cr | 48.5 | |
| 3 | 40%+ | Flat | ₹3,514 Cr | 4.3 | |
| 4 | 40%+ | Flat | ₹180 Cr | 11.9 | |
| 5 | 40%+ | Flat | ₹138 Cr | 15.1 | |
| 6 | 20–40% | Up 2%+ | ₹1.70L Cr | 85.4 |
Sign up free to see every company in the sector ranking and track DCM Shriram Fine Chemicals.
Pro shows every company guiding 40%+ revenue growth →Full Chemicals & Petrochemicals rankingFinancials of DCM Shriram Fine Chemicals
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of DCM Shriram Fine Chemicals
Quarterly Results
Quarter-by-quarter operating performance
| Dec 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales + | 93.35 | 113.09 | 96.90 | 96.95 | 93.08 |
| Expenses + | 88.47 | 105.46 | 98.39 | 96.63 | 95.59 |
| Operating Profit | 4.88 | 7.63 | -1.49 | 0.32 | -2.51 |
| OPM % | 5.23% | 6.75% | -1.54% | 0.33% | -2.70% |
| Other Income + | 0.99 | 1.01 | 0.68 | 0.81 | 0.74 |
| Interest | 0.41 | 0.50 | 0.22 | 0.24 | 0.69 |
| Depreciation | 2.20 | 2.16 | 2.17 | 2.11 | 2.06 |
| Profit before tax | 3.26 | 5.98 | -3.20 | -1.22 | -4.52 |
| Tax % | 26.69% | 26.09% | -20.94% | 22.13% | -15.27% |
| Net Profit + | 2.39 | 4.42 | -2.53 | -1.49 | -3.83 |
| EPS in Rs | 0.24 | 0.44 | -0.25 | -0.17 | -0.44 |
Financials of DCM Shriram Fine Chemicals
Profit & Loss
Annual income statement trend
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Sales + | 429 | 386 |
| Expenses + | 396 | 382 |
| Operating Profit | 33 | 4 |
| OPM % | 8% | 1% |
| Other Income + | 4 | 3 |
| Interest | 2 | 1 |
| Depreciation | 9 | 8 |
| Profit before tax | 26 | -3 |
| Tax % | 26% | 12% |
| Net Profit + | 19 | -4 |
| EPS in Rs | 1.92 | -0.40 |
| Dividend Payout % | 0% | -99% |
Financials of DCM Shriram Fine Chemicals
Balance Sheet
Capital structure and asset base
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 17 | 17 |
| Reserves | 198 | 194 |
| Borrowings + | 13 | 13 |
| Other Liabilities + | 80 | 72 |
| Total Liabilities | 308 | 295 |
| Fixed Assets + | 130 | 103 |
| CWIP | 0 | 0 |
| Investments | 23 | 33 |
| Other Assets + | 155 | 159 |
| Total Assets | 308 | 295 |
Financials of DCM Shriram Fine Chemicals
Cash Flows
Operating, investing and financing cash movement
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Cash from Operating Activity + | 14 | 16 |
| Cash from Investing Activity + | 0 | 11 |
| Cash from Financing Activity + | -15 | -6 |
| Net Cash Flow | 0 | 21 |
| Free Cash Flow | 12 | 35 |
| CFO/OP | 72% | 565% |
Financials of DCM Shriram Fine Chemicals
Ratios
Working capital efficiency and return ratios
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor Days | 70 | 67 |
| Inventory Days | 74 | 64 |
| Days Payable | 80 | 78 |
| Cash Conversion Cycle | 65 | 53 |
| Working Capital Days | 72 | 78 |
| ROCE % | -1% |
Continue your research
Others in Chemicals & Petrochemicals this season
- J.G.Chemicals (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹3,610 million, up 63.9% YoY (₹2,203 million in Q2 FY26) (Page 23) . Key investor presentation takeaways from J.G.Chemicals Ltd
- Lords Chloro (Q2 FY27)
115.40 Crore, up 17.34% YoY from Rs. Key investor presentation takeaways from Lords Chloro Alkali Ltd's Q2 FY27 investor presentation — and how it ranks against
- Camlin Fine (Q2 FY27)
Q2 FY27 revenue: Rs 4,915 mn, up 9.15% YoY from Rs 4,503 mn in Q2 FY26 (Page 6, 9) . Key investor presentation takeaways from Camlin Fine Sciences Ltd's Q2 FY27
- Gujarat Fluoroch (Q2 FY27)
Consolidated Q2FY27 revenue: ₹1,760 crore, up 45% YoY (Q2FY26: ₹1,210 crore). Key investor presentation takeaways from Gujarat Fluorochemicals Ltd's Q2 FY27 inv